
VCs on AI flight to valley
Empower your mind, elevate your skills
ETtech
Indian venture investors are setting up shop in San Francisco, the AI epicenter, as they chase cutting edge development of the technology and aim to spot the next wave of AI trends.Multiple Indian venture capital companies, such as Elevation Capital and Peak XV , have set up shop at AI epicenter, San Francisco, in the US to tap into the booming industry.In addition to this, investors are spending more time in San Francisco or SF as it is called, as the pace of AI development grows unabated in the region.Elevation Capital recently hired Capillary Technologies cofounder and former Meta executive Krishna Mehra, as the AI partner, with more people from the team spending significant time in the US. Peak XV has set up an office in SF, and has hired Arnav Sahu, former Y Combinator principal, to drive investments. Blume Ventures ' managing partner Sanjay Nath is spending time in San Francisco and India.ET has also learnt that VC firm Z47 is looking to expand its presence in San Francisco, in the US. The email sent to the company did not elicit any response till the time of publishing.Krishna Mehra, AI Partner, Elevation Capital, who is based in Palo Alto, quipped that it is now easier to meet a VC in the Valley than in Bengaluru. 'I end up meeting more people from the investment community there,' he says.There are a few things driving this.Mehra explained that this is a combination of more action happening in the US and the need to be closer to understand what is happening in the region and where the buck is going. 'There is a lot of cross border action happening as well, which being there helps to a certain extent,' he added.Two Bengaluru-based investors ET spoke to said that they are travelling to the US more often to understand how the technology is evolving. 'Travelling there iseye-opening in terms of what is happening in AI and the kind of talent density that is available there,' one of the investors said.Anand Krishna, founder, Inkle, a US accounting and tax automation startup, said this is happening globally as well. For instance, he highlighted that a global accelerator, which had originally encouraged founders to start the company wherever they were, is now encouraged to move to the US.'Their original pitch was that build wherever you are, talent is everywhere and sit anywhere in the world. This was 10 years ago,' Krishna said.'This is because the early-stage AI startup has centralised itself to San Francisco city, which has become centre of gravity for startups and foundational model companies. This has eroded Silicon Valley's relative historical dominance over SF, as thousands moved to or launched in the city,' he explained.This includes OpenAI and Y Combinator companies that are in SF that have created a concentration of talent in the region resulting in a vibrant AI ecosystem , attracting investors, startups and techies. 'Now you will see entrepreneurs and investors all over the world making pilgrimages to SF every six to 12 months,' Inkle's Krishna says.Indian investors have been investing aggressively in the AI space in recent times. With a lot of startups in the AI space moving to the US, it is also becoming important for investors to help them with the networks.ET had earlier reported that a number of AI startups such as Smallest.ai, and Composio have moved to SF to tap into this ecosystem.Early this year, Sarvam AI, which is building an Indic foundational model, launched Sarvam Labs in the Bay Area in the US in March in LightSpeed office in Menlo Park, US.Sateesh Andra, managing director, Endiya Partners, who has been spending 3-4 months a year in the US, said, 'They (portfolio startups) need connections and networks. So, helping them becomes very important,' he said. But he does not see himself spending more than that in the region.Elevation Capital's Mehra said that in the last two years they have invested in 15-20 companies, compared to the norm of five or six before, primarily driven by AI. 'There is a lot of potential to build category leading companies, some of them in India. But some of them are easier to do in the US. That is why founders are moving early, and the pool is much larger. This might change in five years,' he said.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Hindu
29 minutes ago
- The Hindu
Business partnerships, direct flights on cards to boost Kazakhstan, Telangana ties
Hyderabad-based MSN Laboratories has entered into an MoU with Kazakh Invest for establishing a pharmaceutical manufacturing facility in Kazakhstan. A few other entities were also exploring business opportunities in Kazakhstan. Discussions are under way to launch direct flights between Hyderabad and Almaty, Honorary Consul of Kazakhstan Nawab Mir Nasir Ali Khan informed Telangana Deputy Chief Minister Mallu Bhatti Vikramarka during a meeting. The Deputy Chief Minister assured government of Telangana's support for such initiatives. He also accepted Mr. Khan's formal invitation to visit Kazakhstan, a release on the meeting aimed at deepening the economic and cultural ties said. The focus was on expanding bilateral trade, healthcare, education and connectivity. Mr. Khan said he recently met Head of Airline Marketing and Route Development at GMR Airport Ananda Acharya to initiate the possibility of launching a direct air connectivity as that would boost tourism, trade and cultural exchange. He also informed Mr. Bhatti about discussions with CEO of Apollo Hospitals Group Srinivas Rao for setting up a medical education institution and a world-class hospital in Kazakhstan.
&w=3840&q=100)

Business Standard
34 minutes ago
- Business Standard
Swiggy unveils ‘99 store' What it is and how it works Budget-friendly meals
Swiggy unveils '99 store' | What it is and how it works | Order food online | Budget-friendly meals Swiggy has introduced a new '99 Store' feature on its app, offering single-serve meals at just ₹99 in over 175 Indian cities. The is designed to attract Gen Z users and budget-conscious customers. Here's everything you need to know about Swiggy's most value-driven food delivery offering yet.
&w=3840&q=100)

Business Standard
34 minutes ago
- Business Standard
Dr Reddy's expects US sales dip in FY26, aims for resilience via scale-up
Hyderabad-based pharmaceutical major Dr Reddy's Laboratories (DRL) has said it is prepared to address an anticipated decline in sales in the United States in FY26 through a combination of organic and inorganic strategies. In a joint message to stakeholders, DRL's chairman K Satish Reddy and co-chairman and managing director G V Prasad said one of the company's key products in the US will face increased competition starting February 2026, likely leading to a fall in sales and profits. 'We have been preparing for this through FY25, through a combination of organic and inorganic strategies,' the message added. DRL stated that in FY26, it aims to grow and strengthen its core businesses and enhance value through portfolio management and strategic differentiation. The company also plans to scale its presence in consumer healthcare, innovative therapies and biosimilars, introduce new revenue streams through acquisitions and partnerships, and streamline structural costs to cushion the impact. For FY25, DRL recorded a 17 per cent rise in total revenue from operations—from ₹27,916 crore in FY24 to ₹32,554 crore. According to the company's investor presentation, North America contributed 45 per cent of DRL's full-year revenue. 'In the US, growth was steady and matched market pace, supported by new launches, Lenalidomide sales, and a stable base business,' the company noted in its annual report filed with the exchanges. The drugmaker has been targeting a larger share of the US market through a dual-track strategy: reinforcing its core business of branded generics, biosimilars and over-the-counter (OTC) drugs, while also investing in growth areas such as consumer healthcare, biosimilars and novel molecules including new chemical entities (NCEs) and CAR-T therapies. 'Leveraging our distribution capabilities, we entered into a nutrition venture with Nestlé in India, received US rights for Cyclophosphamide from Ingenus, and launched Galvus (anti-diabetes) in Russia,' DRL said. The company also highlighted that its subsidiary, Aurigene, received US FDA approval for two oncology assets—AUR110 for solid tumours and AUR112 for lymphoid malignancies—and has filed for approval of the osteoporosis drug Denosumab in the US and Europe. 'These initiatives are in line with our strategy to address issues of availability and accessibility of affordable innovation through in-house and collaborative efforts,' the annual report stated. On Wednesday, DRL's share closed 0.41 per cent lower at ₹1,271.75 apiece on the Bombay Stock Exchange (BSE).